Overview

Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation

Status:
Unknown status

Trial end date:
2017-12-01

Target enrollment:

Participant gender:

Summary

This is a randomized ,opened, prospective controlled trial of clinical effectiveness for Icotinib as the adjunctive treatment after surgery in stage I-IIIB lung adenocarcinoma patients with epidermal growth factor receptor gene mutation

Phase:

Phase 4

Details

Lead Sponsor:

Chinese PLA General Hospital

Treatments:

Carboplatin
Docetaxel